Monthly ibandronate versus weekly risedronate treatment for low bone mineral density in stable renal transplant patients

被引:9
|
作者
Sanchez-Escuredo, Ana [1 ]
Fuster, David [2 ]
Rubello, Domenico [4 ]
Muxi, Africa [2 ]
Ramos, Ana [3 ]
Campos, Francisco [2 ]
Marzola, Maria Cristina [4 ]
Cook, Gary J. [5 ]
Tapias, Andres [2 ]
Torregrosa, Jose-Vicente [1 ]
机构
[1] Hosp Clin Barcelona, Dept Nephrol & Renal Transplant, Barcelona, Spain
[2] Hosp Clin Barcelona, Dept Nucl Med, Barcelona, Spain
[3] Fdn Jimenez Diaz, Dept Nephrol, E-28040 Madrid, Spain
[4] Santa Maria Della Misericordia Hosp, Dept Nucl Med, I-45100 Rovigo, Italy
[5] Kings Coll London, Div Imaging Sci & Biomed Engn, Dept Canc Imaging, London, England
关键词
biphosphonates; bone mineral density; ibandronate; renal transplant; risedronate; BISPHOSPHONATES; OSTEOPOROSIS;
D O I
10.1097/MNM.0000000000000316
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
IntroductionBisphosphonates may aid in treating and preventing bone loss promoted by chronic immunosuppressive treatment and secondary hyperparathyroidism in renal transplant (RT) patients. However, the effectiveness of bisphosphonates is compromised by poor patient compliance. The objective of the study was to compare the effects of once monthly ibandronate with those of weekly risedronate administration on bone mineral density (BMD) and renal function in RT patients.Patients and methodsSixty-nine patients were prospectively recruited who were at least 12 months post-RT and were treated with either oral ibandronate 150mg monthly (n=35) or oral risedronate 35mg weekly (n=34). At baseline and 1 year, creatinine, calcium, alkaline phosphatase, and i-parathyroid hormone were measured, and BMD was determined by dual-energy X-ray absorptiometry.ResultsGroup I consisted of 35 patients (28 women) treated with ibandronate who were of a mean age of 6312 years. Group II consisted of 34 patients (30 women) treated with risedronate who were of a mean age of 64 +/- 10 years. Lumbar BMD was as follows: baseline T-score (group I vs. group II) of -1.7 +/- 0.8 versus -1.9 +/- 0.8 (P=NS); and annual T-score of -1.3 +/- 0.6 versus -1.4 +/- 0.8 (P=NS). After 1 year, lumbar BMD improved to reveal a T-score of -1.3 +/- 0.6 in the ibandronate group (P<0.01) and -1.4 +/- 0.8 in the risedronate group (P<0.01). Femoral BMD was as follows: baseline T-score (group I vs. group II) of -2.1 +/- 0.7 versus -2.2 +/- 0.6 (P=NS); and annual T-score of -1.8 +/- 0.9 versus -1.8 +/- 0.8 (P=NS). Cortical bone also improved in both groups, but results were not statistically significant. No changes in renal function and no adverse effects were observed.ConclusionIn RT patients with low BMD, no difference in effects on BMD, renal function, or adverse effects were observed between monthly oral ibandronate and weekly oral risedronate administration.
引用
收藏
页码:815 / 818
页数:4
相关论文
共 50 条
  • [1] COMPARISON OF THE EFFECTIVENESS OF MONTHLY INTRAVENOUS IBANDRONATE AND MONTHLY ORAL IBANDRONATE IN HEMODIALYSIS PATIENTS WITH LOW BONE MINERAL DENSITY
    Fujii, Takayuki
    Koshizaka, Junya
    Yamauchi, Nobuaki
    Saito, Kaiji
    Morimoto, Mayu
    Terasaki, Noriko
    Tanaka, Hiroaki
    Suzuki, Satoshi
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 : 560 - 560
  • [2] Ibandronate in stable renal transplant recipients with low bone mineral density on long-term follow-up
    Tillmann, F. P.
    Schmitz, M.
    Jaeger, M.
    Krauspe, R.
    Rump, L. C.
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2016, 48 (02) : 279 - 286
  • [3] Ibandronate in stable renal transplant recipients with low bone mineral density on long-term follow-up
    F. P. Tillmann
    M. Schmitz
    M. Jäger
    R. Krauspe
    L. C. Rump
    International Urology and Nephrology, 2016, 48 : 279 - 286
  • [4] Similar bone mineral density gain for oral monthly ibandronate and weekly alendronate in postmenopausal osteoporosis
    Sunyecz, John
    Cosman, Felicia
    Miller, Paul
    Kohles, Joseph D.
    Dasic, Gorana
    Recker, Robert
    OBSTETRICS AND GYNECOLOGY, 2008, 111 (04): : 10S - 10S
  • [5] Comparison of Monthly Ibandronate Versus Weekly Risedronate in Preference, Convenience, and Bone Turnover Markers in Korean Postmenopausal Osteoporotic Women
    Chung, Yoon-Sok
    Lim, Sung-Kil
    Chung, Ho-Yeon
    Lee, In-Kyu
    Park, Il-Hyung
    Kim, Ghi-Su
    Min, Yong-Ki
    Kang, Moo-Il
    Chung, Dong-Jin
    Kim, Yong-Ki
    Choi, Woong Hwan
    Shong, Min Ho
    Park, Ji-Hyun
    Byun, Dong-Won
    Yoon, Hyun-Koo
    Shin, Chan Soo
    Lee, Yil-Seob
    Kwon, Nam-Hee
    CALCIFIED TISSUE INTERNATIONAL, 2009, 85 (05) : 389 - 397
  • [6] Comparison of Monthly Ibandronate Versus Weekly Risedronate in Preference, Convenience, and Bone Turnover Markers in Korean Postmenopausal Osteoporotic Women
    Yoon-Sok Chung
    Sung-Kil Lim
    Ho-Yeon Chung
    In-Kyu Lee
    Il-Hyung Park
    Ghi-Su Kim
    Yong-Ki Min
    Moo-Il Kang
    Dong-Jin Chung
    Yong-Ki Kim
    Woong Hwan Choi
    Min Ho Shong
    Ji-Hyun Park
    Dong-Won Byun
    Hyun-Koo Yoon
    Chan Soo Shin
    Yil-Seob Lee
    Nam-Hee Kwon
    Calcified Tissue International, 2009, 85 : 389 - 397
  • [7] Efficacy and Safety of Once Monthly Ibandronate Treatment in Patients with Reduced Bone Mineral Density - ESTHER Study
    Vujasinovic Stupar, Nada
    Milic, Natasa
    Petrovic-Rackov, Ljiljana
    Prodanovic, Nenad
    Mijailovic-Ivkovic, Milena
    Grujic, Zoran
    Bukovic, Stevan
    Novkovic, Snezana
    Pasalic-Simic, Katarina
    Petrovic, Vera
    Vukasinovic, Dragan
    Perunicic, Gordana
    SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2010, 138 (1-2) : 56 - 61
  • [8] EFFECT OF MONTHLY INTRAVENOUS IBANDRONATE INJECTIONS ON BONE MINERAL DENSITY IN JAPANESE OSTEOPOROSIS PATIENTS
    Ikeda, S.
    Tanaka, H.
    Murai, T.
    Tamaru, M.
    Matsumoto, H.
    Okimoto, N.
    OSTEOPOROSIS INTERNATIONAL, 2016, 27 : S379 - S380
  • [9] Higher response with bone mineral density increase with monthly injectable ibandronate 1 mg compared with oral risedronate in the MOVER study
    Nakano, Tetsuo
    Yamamoto, Masao
    Hashimoto, Junko
    Tobinai, Masato
    Yoshida, Seitaro
    Nakamura, Toshitaka
    JOURNAL OF BONE AND MINERAL METABOLISM, 2016, 34 (06) : 678 - 684
  • [10] Higher response with bone mineral density increase with monthly injectable ibandronate 1 mg compared with oral risedronate in the MOVER study
    Tetsuo Nakano
    Masao Yamamoto
    Junko Hashimoto
    Masato Tobinai
    Seitaro Yoshida
    Toshitaka Nakamura
    Journal of Bone and Mineral Metabolism, 2016, 34 : 678 - 684